| abstract |
The present invention relates to influenza A virus variants, particularly variants that are resistant to polymerase inhibitors. Methods and compositions relating to influenza A virus variants are also provided. Further provided are methods for isolating, identifying, and characterizing a plurality of viral variants from a patient. An isolated influenza A virus polynucleotide, biologically active analogue thereof, or biologically active fragment thereof comprising a mutation in the gene encoding influenza A virus polymerase, The mutation has at least one amino acid substitution corresponding to an amino acid residue selected from the group consisting of amino acids 306, 323, 324, 325, 357, 376, 404, 406, 431, and 510 of wild type influenza A virus. Resulting in an isolated influenza A virus polynucleotide, a biologically active analog thereof, or a biologically active fragment thereof. |